Overall rank by patents
#47,768
Across all tracked assignees
USPTO PatentsView assignee record - 5 granted patents across 2 technology areas, active 2019–2021. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G09F (DISPLAYING; ADVERTISING; SIGNS; LABELS OR NAME-PLATES; SEALS).
The verdict
In holds 5 US patents across 2 technology areas, rank #47,768 of 50,000 tracked assignees.
In The Black Revocable Trust has been granted 5 US utility patents between 2019 and 2021, placing In The Black Revocable Trust at rank #47,768 across all assignees tracked by PlainPatent. This portfolio spans 2 distinct Cooperative Patent Classification (CPC) subclasses, averaging 2.6 claims per patent with primary concentration in G09F (DISPLAYING; ADVERTISING; SIGNS; LABELS OR NAME-PLATES; SEALS). As a US Corporation, In The Black Revocable Trust is one of the more focused assignees in the PatentsView dataset. By volume, In sits between Immunomolecular Therapeutics, Inc. (5 patents, rank #47,764) and Incipio Devices Sa (5 patents, rank #47,772) - the closest US assignees by grant volume. The composite Innovation Score of 12.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 3 grants, compared with 2 in the 2015–2019 window, a +50% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. In The Black Revocable Trust's 2.6 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while specialization in 2 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark In The Black Revocable Trust against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
ImmunoMolecular Therapeutics, Inc.
5 patents
Immunology Laboratories, Inc.
5 patents
Immy Inc.
5 patents
Impact Solutions
5 patents
InTunes Products, LLC
5 patents
Incanthera Ltd
5 patents
Inception Innovations, Inc.
5 patents
Incipio Devices SA
5 patents
In The Black Revocable Trust
5 patents
What this shows In holds 5 patents at rank #47,768, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #47,768 in granted patent volume.
Other assignees with the most granted patents in In's primary technology class.
In's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
13 Top 98% higher than 2% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 2 | 40.0% |
| 2020 | 2 | 40.0% |
| 2021 | 1 | 20.0% |
Top 2 of 2 technology areas
Overall rank by patents
#47,768
Across all tracked assignees
12.8 out of 100
How to use this portfolio
In's 5 grants land it in the top 98% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.